Received Oct 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 9PT2F | IM |
Infanrix was administered to an adult/ Vaccine underdose; The administration of Infanrix instead of Boostrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 79-year-old male patient who received DTPa (Infanrix) (batch number 9PT2F, expiry date 10-MAR-2026) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On 16-SEP-2025, the patient received Infanrix (intramuscular, unknown deltoid). The patient did not receive Boostrix. The patient experienced inappropriate age at vaccine administration (Verbatim: Infanrix was administered to an adult/ Vaccine underdose) and wrong vaccine administered (Verbatim: The administration of Infanrix instead of Boostrix). The outcome of the inappropriate age at vaccine administration and wrong vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt date: 17-SEP-2025 The HCP reports that on 16-Sep-2025 a dose of Infanrix was administered to an adult patient. The vaccine should have been Boostrix.